Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases
“The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives laboratories the ability to process latent TB tests at higher volumes without compromising clinical accuracy,” said Yves Dubaquie, senior vice president, diagnostics at Revvity. “By automating T-SPOT.TB testing, we are empowering laboratories with increased throughput and reliability, ultimately leading to better patient outcomes.”
Key Features of the Automated Latent Tuberculosis Test
- The Auto-Pure 2400 system seamlessly integrates liquid handling and magnetic cell isolation technology.
- The Auto-Pure 2400 system streamlines lab workflows, testing up to 24 samples per run, completing Day 1 of the T-SPOT.TB testing in under 3.5 hours with only a single mid-run user interaction.
- The WHO identifies T-SPOT.TB as the only ELISPOT-based IGRA. This methodology, with its added cell number normalization step, ensures reproducible results by minimizing the impact of pre-analytical variables seen in other IGRAs.
- The T-SPOT.TB test delivers key advantages, including fewer indeterminate results, reduced need for repeat testing, and consistent performance in immunocompromised patients.
For In Vitro Diagnostic Use. Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.
About Revvity
At Revvity, we turn "impossible" into innovation and transform scientific challenges into breakthroughs. We deliver cutting-edge solutions in diagnostics, translational multi-omics, biomarker discovery, imaging, screening, and informatics—helping our customers move from research to real-world impact.
With 2024 revenue of more than
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402936376/en/
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Media Contact:
Chet Murray
(781) 462-5126
chet.murray@revvity.com
Source: Revvity